Stockholm – November 20, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established.
According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the Annual General Meeting 2027 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2026 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
The Nomination Committee in respect of the Annual General Meeting 2027 consists of the following persons, who together represent approximately 16 percent of the votes in the company based on shareholder information at the end of September 2026:
- Staffan Lindstrand, appointed by HealthCap VI L.P. and HealthCap VIII L.P.
- Ulf Nolén, representing his own shareholding
- Philip Lennhammer, appointed by Madeleine Lennhammer
- Per Wold-Olsen, Chairman of the Board
The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2027 and on Oncopeptides’ website, www.oncopeptides.com.
Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to info@oncopeptides.com (subject “Nomination Committee”) or by letter to:
Oncopeptides AB (publ)
Attn: Oncopeptides Nomination Committee
Luntmakargatan 46
SE-111 37 Stockholm
Sweden
Proposals must reach the Nomination Committee no later than April 1, 2027, to be eligible for inclusion in the notice and agenda for the Annual General Meeting.